Association of maternal serum high sensitive C‐reactive protein level with body mass index and severity of pre‐eclampsia at third trimester

Ertaş, İbrahim Egemen; Kahyaoğlu, Serkan; Yılmaz, Bülent; Özel, Murat; Süt, Necdet; Güven, Melih; Danışman, Nuri

doi:10.1111/j.1447-0756.2010.01279.x

Cited by 40 publications

(43 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thirty‐two studies in total reported on C‐reactive protein levels,21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52 of which 17 were applicable for meta‐analysis 21, 22, 23, 29, 30, 31, 32, 33, 34, 37, 38, 39, 41, 42, 47, 49, 50. A significantly higher C‐reactive protein was found in women with pre‐eclampsia than in non‐hypertensive controls ( Figure 2), and this correlation was stronger in severe than in mild pre‐eclampsia ( Figure 3).…”

Section: Resultsmentioning

confidence: 99%

Shared biomarkers between female diastolic heart failure and pre‐eclampsia: a systematic review and meta‐analysis

et al. 2017

View full text Add to dashboard Cite

Evidence accumulates for associations between hypertensive pregnancy disorders and increased cardiovascular risk later. The main goal of this study was to explore shared biomarkers representing common pathogenic pathways between heart failure with preserved ejection fraction (HFpEF) and pre‐eclampsia where these biomarkers might be potentially eligible for cardiovascular risk stratification in women after hypertensive pregnancy disorders. We sought for blood markers in women with diastolic dysfunction in a first literature search, and through a second search, we investigated whether these same biochemical markers were present in pre‐eclampsia.This systematic review and meta‐analysis presents two subsequent systematic searches in PubMed and EMBASE. Search I yielded 3014 studies on biomarkers discriminating women with HFpEF from female controls, of which 13 studies on 11 biochemical markers were included. Cases had HFpEF, and controls had no heart failure. The second search was for studies discriminating women with pre‐eclampsia from women with non‐hypertensive pregnancies with at least one of the biomarkers found in Search I. Search II yielded 1869 studies, of which 51 studies on seven biomarkers were included in meta‐analyses and 79 studies on 12 biomarkers in systematic review.Eleven biological markers differentiated women with diastolic dysfunction from controls, of which the following 10 markers differentiated women with pre‐eclampsia from controls as well: C‐reactive protein, HDL, insulin, fatty acid‐binding protein 4, brain natriuretic peptide, N terminal pro brain natriuretic peptide, adrenomedullin, mid‐region pro adrenomedullin, cardiac troponin I, and cancer antigen 125.Our study supports the hypothesis that HFpEF in women shares a common pathogenic background with pre‐eclampsia. The biomarkers representing inflammatory state, disturbances in myocardial function/structure, and unfavourable lipid metabolism may possibly be eligible for future prognostic tools.

show abstract

Section: Resultsmentioning

confidence: 99%

Shared biomarkers between female diastolic heart failure and pre‐eclampsia: a systematic review and meta‐analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Its sensitivity is high but non specific in nature. CRP levels are elevated in healthy pregnant women compared with non-pregnant women, although to a lesser extent than that seen in PE 10 .…”

mentioning

confidence: 92%

Association of Serum C-reactive Protein in Preeclampsia and its Effect on Fetal Birth Weight A Case Control Study

Sharmin

Chy

Alam

et al. 2017

Bangladesh J Obstet Gynaecol

View full text Add to dashboard Cite

show abstract

“…10, 11 Notably, previous human studies report that circulating CRP is elevated in preeclamptic patients and its elevation is correlated to the clinical symptoms. 12, 13 Moreover, plasma CRP is found to be elevated prior to maternal disease development in patients with PE, 12, 14, 15 implicating that CRP is likely a pre-symptomatic biomarker for early detection. However, the functional role of circulating CRP in PE remains unknown.…”

Section: Introductionmentioning

confidence: 99%

Neurokinin 3 Receptor and Phosphocholine Transferase

et al. 2015

View full text Add to dashboard Cite

C-reactive protein (CRP), an innate immune mediator, is elevated in the circulation prior to symptoms in patients with preeclampsia (PE), a severe hypertensive pregnancy disorder with high mortality and morbidity. However, the specific sources underlying increased CRP and the role of elevated CRP in PE are undefined. Here, we report that circulating CRP levels are significantly increased in a large cohort of normotensive pregnant individuals compared to nulligravid women and is further increased in PE patients. These findings led us to further discover that placental syncytiotrophoblasts are previously unrecognized cellular sources of CRP and underlie elevated CRP in normotensive pregnant women and the additional increase in PE patients. Next, we demonstrated that injection of CRP induces PE features including hypertension (157.08 mmHg CRP treated vs. 118.99 mmHg control), proteinuria (35.0 mg/μg CRP treated vs. 14.1 mg/μg control), kidney and placental damage and increased levels of sFlt-1 in pregnant mice but not nonpregnant mice. We hypothesize that phosphocholine transferase, a placental specific enzyme posttranslationally modifying neurokinin B (NKB), is essential for the pathogenic role of CRP in PE through activation of the neurokinin 3 receptor. Overall, our studies have provided significant new insight regarding the pathogenic role of CRP in PE and highlighted innovative therapeutic strategies.

show abstract

Association of maternal serum high sensitive C‐reactive protein level with body mass index and severity of pre‐eclampsia at third trimester

Abstract: Elevated level of hs-CRP is a useful parameter in the severity of clinical risk of pre-eclampsia in patients with BMI < 25 kg/m(2) at third trimester.

Cited by 40 publications

References 33 publications

Shared biomarkers between female diastolic heart failure and pre‐eclampsia: a systematic review and meta‐analysis

Shared biomarkers between female diastolic heart failure and pre‐eclampsia: a systematic review and meta‐analysis

Association of Serum C-reactive Protein in Preeclampsia and its Effect on Fetal Birth Weight A Case Control Study

Neurokinin 3 Receptor and Phosphocholine Transferase

Contact Info

Product

Resources

About

Association of maternal serum high sensitive C‐reactive protein level with body mass index and severity of pre‐eclampsia at third trimester

Abstract: Elevated level of hs-CRP is a useful parameter in the severity of clinical risk of pre-eclampsia in patients with BMI < 25 kg/m(2) at third trimester.

Cited by 40 publications

References 33 publications

Shared biomarkers between female diastolic heart failure and pre‐eclampsia: a systematic review and meta‐analysis

Shared biomarkers between female diastolic heart failure and pre‐eclampsia: a systematic review and meta‐analysis

Association of Serum C-reactive Protein in Preeclampsia and its Effect on Fetal Birth Weight  A Case Control Study

Neurokinin 3 Receptor and Phosphocholine Transferase

Contact Info

Product

Resources

About

Association of Serum C-reactive Protein in Preeclampsia and its Effect on Fetal Birth Weight A Case Control Study